Hua Medicine (Shanghai) Ltd. (2552.HK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Li Chen Ph.D. | Founder, CEO & Executive Director | 8.64M | -- | 1963 |
| Mr. Chien Cheng Lin J.D. | Executive VP & Chief Strategy Officer | 6.58M | -- | 1971 |
| Dr. Fuxing Tang Ph.D. | CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA | -- | -- | 1967 |
| Dr. Changhong Li Ph.D. | Chief Scientific Officer | -- | -- | 1969 |
| Mr. Chengde Wang | Head of IR | -- | -- | 1948 |
| Dr. Yi Zhang M.D., Ph.D. | Senior VP of Pharma Development, Chief Medical Officer ? China and Executive Director | -- | -- | 1975 |
| Mr. Ying Xie M.B.A. | VP of Quality Assurance Division & Chief Quality Officer | -- | -- | -- |
| Ms. Wing Yan Yuen FCIS, FCS | Company Secretary | -- | -- | 1970 |
Hua Medicine (Shanghai) Ltd.
- Sector:?
- Healthcare
- Industry:? Drug Manufacturers - Specialty & Generic
- Full Time Employees:?
- 172
Description
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. The company also offers Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. The company was incorporated in 2011 and is based in Shanghai, China.
Corporate Governance
Upcoming Events
August 29, 2024 at 10:59 AM UTC
Hua Medicine (Shanghai) Ltd. Earnings Date
Recent Events
Recent Events Information Not Available